Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | NHERF1 | O14745 | 2/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710125 | 0.91 | SERPINE1 (0.48) | NHERF1SERPINE1PLCG2MAPTF10 | |
| SCHEMBL6712183 | 0.90 | ALDH1A1 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4HTT | |
| SCHEMBL6710216 | 0.90 | KCNMA1 (0.46) | NHERF1HTTPLCG2PYGL | |
| SCHEMBL6713754 | 0.90 | SERPINE1 (0.43) | NHERF1SERPINE1PLCG2 | |
| SCHEMBL6712030 | 0.88 | CHRNB2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4HTT | |
| SCHEMBL6711906 | 0.87 | NHERF1 (0.46) | NHERF1PLCG2F10PYGL | |
| SCHEMBL6707792 | 0.86 | NHERF1 (0.40) | NHERF1HTT | |
| SCHEMBL6708001 | 0.86 | MEN1 (0.45) | TDP1MAPT | |
| SCHEMBL6711851 | 0.86 | PTGES (0.40) | NHERF1PLCG2F10 | |
| SCHEMBL6710112 | 0.86 | MAP3K5 (0.45) | NHERF1TDP1PLCG2MAPTF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | CHRNB2 4882/4885CHRNB4 4880/4885CHRNA3 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.